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OBJECTIVES: Major depressive disorder (MDD) is an important public health prob-
lem in South Korea, with a lifetime prevalence of 6.7%. Current antidepressants do 
not fully meet needs in depression, so additional options are required. We assessed 
the cost-utility of vortioxetine (a new antidepressant with multimodal activity) ver-
susvenlafaxine XR in MDD patients in South Korea initiating these antidepressants 
or switching to them due to inadequate response to previous treatment. METHODS: 
A one-year cost-utility analysis from a societal perspective was performed using 
an initial decision-tree model, which included suicide risk, followed by a Markov 
model (2-month cycles) for subsequent treatments. Remission, relapse and recovery 
were the main health states. In first line, efficacy at two months was derived from 
the Asian SOLUTION study (vortioxetine vs. venlafaxine XR; NCT01571453) and for 
switching patients from REVIVE (vortioxetine vs. agomelatine; NCT01488071) and 
STAR*D (pragmatic trial of several antidepressants). STAR*D was the efficacy source 
for subsequent lines of treatment. Adverse event probabilities were included to 
consider the impact on quality of life and costs. Utilities were derived from REVIVE 
and adverse event disutilities from the literature. Resource use and productivity 
estimates were obtained from a survey of 28 Korean physicians. Korean 2013/2014 
costs were applied. Deterministic and probabilistic sensitivity analyses were con-
ducted. RESULTS: Vortioxetine dominated venlafaxine XR, with QALY gains of 
0.0155 and a cost difference of KRW 576,433 [US$532] (KRW 3,334 [US$3] when pro-
ductivity not considered) over one year. The model showed a greater proportion 
of patients in recovery after initial treatment with vortioxetine (31.4%) compared 
with venlafaxine XR (23.4%). These results were confirmed to be robust through 
sensitivity analysis; vortioxetine remained dominant in 97% of probabilistic simula-
tions. CONCLUSIONS: Vortioxetine dominated venlafaxine XR in South Korea and 
therefore appears to be a relevant treatment option for MDD patients initiating or 
switching therapy.
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OBJECTIVES: To evaluate the cost-effectiveness of bipolar disorder (I and II) treat-
ments to assist in efficient resource allocation. METHODS: A population based 
model was developed to estimate the cost per disability adjusted life year (DALY) 
averted for efficacious therapies to treat adults with bipolar disorder. The model is 
based on the 2013 Australian population with the Global Burden of Disease (GBD) 
prevalence estimates applied. All-cause mortality attributable to bipolar disorder 
is incorporated as well as the decreased rate of suicide attributable to lithium. 
Disability weights from GBD are used to calculate DALYs. The evaluation takes a 
health sector perspective and used standard costs for medications and other medi-
cal services obtained from Australian sources. All treatments with proven efficacy 
were sourced from current systematic reviews/meta-analyses and supplemented 
with expert clinical input. Treatments evaluated included monotherapy with atypi-
cal antipsychotics, anticonvulsants, and lithium as well as combination therapies 
evaluated in randomized controlled trials. Psychological therapies were evaluated 
as adjunctive to medications. Electroconvulsive therapy was evaluated as a treat-
ment in the depressive phase only. RESULTS: Preliminary results suggest that 
among monotherapies, valproate produced the lowest cost per/DALY $AUD 53,000/
DALY (CI $35,000 - $84,000). Oxcarbazepine plus lithium provided the lowest cost 
among combinations $104,000/DALY (CI dominant - $446,000). Adding a disorder 
specific psychotherapy was less cost effective than pharmacotherapy alone for 
lower cost treatments (lithium, valproate) and more cost effective for aripiprazole, 
olanzapine, quetiapine, and combinations. Adherence costs will be varied in future 
analysis and presented. CONCLUSIONS: Preliminary results indicate treatments 
generally exceeded the commonly accepted $AUD 50,000/DALY threshold for cost-
effectiveness. From an economic perspective, valproate would be recommended 
as initial therapy. Higher cost therapies, including most combinations, should be 
implemented with a psychological intervention.
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OBJECTIVES: Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed 
antidepressants. This claims database study compared healthcare resource use and 
costs among patients with major depressive disorder (MDD) treated with vilazodone, 
versus other SSRIs. METHODS: Adults with an MDD diagnosis and ≥ 1 prescription 
fill for vilazodone, citalopram, escitalopram, fluoxetine, paroxetine or sertraline 
were identified from the Truven Health MarketScan® Research Databases (January 
1, 2010 to December 31, 2012). Patients who concomitantly used adjunctive medica-
tion, either a second-generation antidepressant or antipsychotic, were excluded. 
All-cause and MDD-related healthcare resource use and costs (measured from a 
payer’s perspective in 2012 US dollars) over a 6 month period post-index date were 
compared among treatment groups using multivariate robust Poisson regression 
and robust linear regression, respectively, adjusted for age, gender, insurance type, 
index year, comorbidities, prior antidepressant treatment, and pharmacy copay-
ment at baseline (12 months pre-index date). RESULTS: The study cohort included 
49,861 patients (mean age: 44.0 years; 70% female). Compared with the vilazodone 
cohort (N= 3,527), patients in the citalopram (N= 12,187), escitalopram (N= 8,275), 
fluoxetine (N= 10,142), paroxetine (N= 3,146), and sertraline (N= 12,584) cohorts had 
significantly more all-cause inpatient (IP) visits, length of IP stay and emergency 
room (ER) visits, and MDD-related IP visits and length of IP stay following the index 
date, after adjusting for baseline characteristics. All-cause medical service costs (IP + 
outpatient + ER) were significantly higher across all other SSRI cohorts versus vilazo-
done by $758 to $1,165 (P< 0.05). Similarly, all-cause total costs were also significantly 
or numerically higher across all SSRI cohorts versus vilazodone by $351 to $780 after 
accounting for prescription costs. CONCLUSIONS: MDD treatment with vilazodone 
was associated with significantly lower rates of inpatient and emergency services, 
and with significantly lower all-cause medical service and numerically lower total 
costs to payers compared to other SSRIs included in this study.
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OBJECTIVES: Describe estimated health resource (HR) and criminal justice (CJ) sys-
tem costs by treatment failure status for young patients with schizophrenia that 
participated in the Paliperidone palmitate Research In Demonstrating Effectiveness 
(PRIDE) clinical trial involving recently incarcerated subjects. METHODS: HR and 
CJ events were collected via a resource use questionnaire and were combined 
with cost estimates obtained from administrative claims and published literature 
to estimate costs at 15 months (trial duration). Treatment failure was defined in 
the clinical trial as having any of the following: an arrest/incarceration, psychi-
atric hospitalization, suicide, discontinuation of antipsychotic treatment due to 
inadequate efficacy, treatment supplementation with another antipsychotic due 
to inadequate efficacy, discontinuation of antipsychotic treatment due to safety 
or tolerability, or increase in the level of psychiatric services in order to prevent 
imminent psychiatric hospitalization. Costs, in 2011 US dollars, were estimated by 
failure status (Yes/No) for young subjects (defined as those ≤ 35 years of age) and 
summarized descriptively using a state government payer perspective. RESULTS: 
Estimated cost per person for young subjects with a failure (n= 104) were $45,590 
versus $24,586 for young subjects without a failure (n= 57). Cost differences were 
greater for the failure group relative to no failure group for criminal justice system 
events ($20,961) acute care events ($4,722) and outpatient care ($524). Within the 
failure group, extrapolating out to the 15 month trial duration, criminal justice 
system events were a common cause of failure in this analysis with an estimated 
86.5% expected to have a criminal justice system contact and 70.2% expected to 
be incarcerated. CONCLUSIONS: From a state government perspective, provision 
of early interventions that reduce treatment failure among young patients may 
avoid substantial cost.
MentAl HeAltH – Patient-reported outcomes & Patient Preference studies
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OBJECTIVES: Life satisfaction is affected by social, economic, disease and health-
related living conditions. Depressive disorders are known to be an important burden 
for life satisfaction, whereas social support from family or peer groups can substan-
tially buffer this impact. The objective of this contribution is to analyse the comple-
mentary influences of depression and social support on life satisfaction. METHODS: 
In 2012, two representative population samples of the non-institutionalized adult 
population in Germany and UK were surveyed (n= 4,008) and self-reports about 
satisfaction with life as a whole, health, social life, functioning, income and social 
life were collected. Five years earlier, in 2007, the same individuals had reported on 
chronic diseases, health care, health status and social and living conditions, as well 
as depression diagnosis and treatment. Multiple linear regression allows to estimate 
the prospective five-year impact of depression, multimorbidity (score of 22 chronic 
diseases) and social support on life satisfaction. RESULTS: In 2007, 13.3% of the 
German and 21.3% of the UK sample had suffered from depression. In 2012, 65.0% of 
the individuals in UK and 73.9% in Germany reported to be “satisfied” or “very satis-
fied” with “life as a whole”. In the group of individuals with “no depression” in 2007, 
75.2% of the individuals reported positive life satisfaction in 2012. Among individu-
als with medically diagnosed depression in 2007, the fraction was 42.3%. Multiple 
linear regression resulted in a strong positive buffering effect of social support 
(beta= .225; p< .00) on life satisfaction and a substantial negative impact of depres-
sion (beta= -.167; p< .00) in 2012. Age had very small effect (beta= .076;p< .00) and the 
influence of gender was not statistically significant. CONCLUSIONS: Depression 
has a negative impact on life satisfaction, which can partly compensated by good 
social support.
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OBJECTIVES: To elicit caregivers’ preferences for evidence-based treatment options 
for their child’s attention deficit hyperactivity disorder (ADHD), and to identify seg-
ments of caregivers who display similar preferences. METHODS: Caregivers with 
a child aged 4–14 and in care for ADHD were recruited from outpatient clinics and 
advocacy groups. All caregivers completed a self-administered survey that included 
socio-demographic information, and a best-worst scaling (BWS) instrument assess-
ing treatment preferences. The BWS instrument comprised 18 choice tasks, each 
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displaying seven treatment attributes: medication, therapy, school involvement, 
caregiver behavior training, physician management, provider communication 
and out-of-pocket costs. Every attribute was operationalized into 3 possible levels. 
Within each task, caregivers selected one best and one worst attribute. A scale-
adjusted latent-class (SALC) analysis was conducted to account for variability in the 
consistency of responses. RESULTS: Our study population of 164 caregivers were 
on average 42 years old (SD 8.7), predominantly female (95%), white (65%), married 
(61%), college-educated (73%), and 20% had a child who was diagnosed with ADHD 
for ≤ 1year. Based on the aggregate results, using medication everyday was the most 
preferred treatment attribute (coefficient= 2.41, p< 0.001). Three latent classes (i.e. 
segments) that best described the data were identified, and the scale factor included 
in the model was significant (p< 0.001). The 3 segments comprised 28%, 27%, and 45% 
of our study population. Segment 1 has the strongest preference for ‘medication’ 
(coefficients= 3.69 –4.34, all p< 0.001) while Segment 2 displayed the least preference 
for medication (coefficients= -1.49 – -3.36, all p< 0.001). Segment 3 was most cost-
avoidant (coefficients= -2.13 – -6.11, all p< 0.001) but had the strongest preference 
for ‘school involvement’ (coefficients= 0.63 – 2.58, all p< 0.05). CONCLUSIONS: This 
study demonstrated variation in caregivers’ priorities for ADHD treatment attrib-
utes. A better understanding of preferences for evidence-based treatment options 
can enhance patient-centered care. By utilizing SALC, our study reduces the likeli-
hood of misclassification error.
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OBJECTIVES: Patient focus groups were conducted to identify the most important 
clinical attributes and outcomes of pharmacological treatments for bipolar depres-
sion influencing patients’ treatment adherence decisions. Qualitative results will 
guide the development of a quantitative discrete choice experiment to determine 
patient preferences and willingness to trade-off between medication character-
istics. METHODS: Adults clinically diagnosed with bipolar I disorder, recently 
depressed, previously/currently treated with antipsychotics, and not currently 
suicidal were recruited from two clinical sites. Following an IRB-approved (E&I 
Review Services) protocol, inclusion criteria, and semi-structured, open-ended 
discussion guide, focus groups lasting 90-minutes were conducted to discuss 
patients’ expectations and experiences towards treatment safety and efficacy. 
Focus groups recordings were transcribed, a data coding dictionary developed, 
and ATLAS.ti used for qualitative data analysis. RESULTS: From the two focus 
groups conducted (n= 8 each; Total N= 16; mean age 47.9±6.4 years; 68.8% female, 
mean time since diagnosis 15.7±11.4 years; mean length of atypical antipsychotic 
use 4.7±4.6 years), participants were most concerned with treatment efficacy, 
expecting a medication to balance the “highs and lows” of bipolar symptoms and 
providing “clarity” (control of thoughts and actions). One in 4 expected symptom 
improvements within 2-3 weeks of treatment initiation, and would tolerate side 
effects and less desirable features, as long as these did not outweigh treatment 
benefits. Side effects mentioned spontaneously and rated most highly by partici-
pants as influencing treatment initiation and persistence decisions were weight 
gain (n= 8, 50.0%) and sedation/fatigue (n= 7, 43.8%). To manage side effects, most 
(n= 7, 43.8%) reported self-treatment by reducing dosage or discontinuing without 
medical consultation. CONCLUSIONS: Treatment efficacy, faster onset in terms of 
symptom improvement, less weight gain, and less severe sedation/fatigue were 
identified as most important outcomes determining patients’ treatment decisions. 
Based on qualitative results, identified treatment attributes will be included in 
a quantitative discrete choice experiment to determine patients’ preferences for 
bipolar depression pharmacological treatments.
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OBJECTIVES: Vortioxetine, a novel antidepressant exhibiting a multimodal mecha-
nism of action, was approved for the treatment of adults with major depressive 
disorder (MDD). This extension study of a recently published meta-analysis (Llorca 
et al. Curr Med Res Opin 2014;30(12):2589-606) compares the efficacy and toler-
ability of vortioxetine with seven commonly used antidepressants marketed in 
the US. METHODS: Indirect comparisons using meta-regression, an extension of 
random-effects meta-analysis, were performed using data from 54 double-blind, 
placebo-controlled Phase 3 pivotal studies identified in a systematic review (N= 
18,312 patients). To ensure study comparability, only experimental drug and pla-
cebo arms were included in primary analyses. Study-level standardized effect sizes 
were regressed on active treatment to compare efficacy and tolerability of vorti-
oxetine with branded (levomilnacipran, vilazodone, desvenlafaxine) and generic 
(duloxetine, escitalopram, sertraline, venlafaxine) antidepressants. Efficacy was 
defined as change from baseline on the Montgomery-Asberg Depression Scale 
or Hamilton Depression Rating Scale after 2 months (6-12 weeks) of treatment. 
Tolerability was defined as the withdrawal rate due to any adverse event. RESULTS: 
Standardized mean differences for vortioxetine compared with the selected anti-
depressants (negative estimates favor vortioxetine) were: duloxetine, 0.10 (95% 
confidence interval [CI]: -0.12, 0.32); escitalopram, -0.04 (95% CI: -0.32, 0.24); ser-
traline, -0.02 (95% CI: -0.39, 0.34); venlafaxine, 0.14 (95% CI: -0.11, 0.39); levom-
ilnacipran, -0.05 (95% CI: -0.28, 0.19); vilazodone, -0.23 (95% CI: -0.53, 0.06); and 
desvenlafaxine, 0.04 (95% CI: -0.16, 0.23). Significantly lower withdrawal rates were 
observed for vortioxetine versus sertraline, venlafaxine, and desvenlafaxine (all 
P< 0.05). No statistically significant difference in withdrawal rates was observed 
between vortioxetine and duloxetine, escitalopram, levomilnacipran, or vilazo-
done. CONCLUSIONS: These findings show that vortioxetine offers a comparable 
combination of efficacy and tolerability in MDD to other antidepressants marketed 
in the US.
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OBJECTIVES: Clinical outcome assessments (COAs) are clinician-reported out-
comes (ClinROs), patient-reported outcomes (PROs), observer-reported outcomes 
(ObsROs), and performance outcomes (PerfROs) tools used to assess the patient’s 
symptom, impact, and overall mental state. PRO measures, specifically developed 
to capture the patients’ perspective without clinician interpretation, are consid-
ered an approved means to support labeling by the Food and Drug Administration 
(FDA). This study aims to identify the extent to which COAs were used to support 
label claims and to identify the prevalence of PRO specific measures in men-
tal health drugs approved by the FDA in the period 2006-2014. METHODS: New 
drugs used to treat mental health conditions approved by the FDA from 2006-2014 
were identified and labels were retrieved from using the Drugs@FDA database. 
The “Indications and Usage” and “Clinical Studies” sections of each label were 
reviewed and relevant indications and concordant COA data was extracted and 
categorized by type using PROQOLID. RESULTS: A total of 20 FDA-approved drugs 
for use in mental health conditions were identified. Of these, 18 labels included 
clinical study data and 14 labels used the results of COAs to support 19 indica-
tions; major depressive disorder (n= 5), schizophrenia and/or schizoaffective dis-
order (n= 5), attention deficit hyperactivity disorder (n= 3), bipolar mania (n= 2), 
insomnia (n= 2), seasonal affective disorder (n= 1), depressive episodes associated 
with bipolar I disorder (n= 1). Clinical studies included 32 COAs used 47 different 
times to support drug/indication labeling; 39 ClinROs, 4 ObsROs, and 4 PerfROs 
(none employed PRO measures). COAs were used to measure primary efficacy 
endpoints (n= 41), to establish safety (n= 2) and to determine study eligibility (n= 7) 
(not mutually exclusive). Thirteen out of 14 labels demonstrated efficacy by using 
a COAs. CONCLUSIONS: All mental health drug labels approved by the FDA since 
2006 utilized clinical outcome assessments to support drug efficacy and labeling, 
however PROs were underutilized.
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OBJECTIVES: This review was designed to synthesize information about the 
impact of major depressive disorder (MDD) on functionality, work performance, 
and potential stigma in the emerging markets of Brazil, China (including Taiwan) 
and Russia. METHODS: Studies indexed in MEDLINE (2004-2014) and abstracts from 
relevant conferences were screened with search terms including “depression/MDD,” 
“productivity/employment,” “functionality,” and “stigma.” RESULTS: Sixteen studies 
were extracted for Brazil, 18 for China and 5 for Russia. There was significant study 
heterogeneity in the study populations and outcome measures in the literature. The 
negative correlation of MDD with functionality and work performance was evident 
across countries. In Brazil, depression increased the risk of unemployment by 39% 
(OR 1.39; 95% CI 1.15-1.67) in one study and was significantly predictive of worse 
hrQoL among subpopulations sampled in other studies (P ≤ .001). Depression was 
associated with decreased work performance (OR 0.91; 95% CI 0.87-0.95) in Chinese 
enterprises. In Taiwan, MDD patients experienced an average 5.8-61 sick-leave days 
annually. Depressed (vs non-depressed) Chinese had a higher risk of impairment 
in activities of daily living (RR 2.20-4.29; 95% CI 1.33-8.86). A Russian study reported 
that depression impacted employment for 31.7% of urban-dwelling adults; 12.2% 
reduced working hours, 17.1% became unemployed and 24.4% took an average 74 
± 54 sick-leave days annually. Stigma caused by cultural and social factors was an 
obstacle to help-seeking, MDD diagnosis and treatment in China and Russia but 
not in Brazil. CONCLUSIONS: MDD is correlated with impaired functionality and 
work performance in Brazil, China and Russia. Stigma specific to national environ-
ment should be addressed to remove barriers to MDD treatment. Future longitu-
dinal inquiry is needed to comprehensively evaluate the consequences of MDD. 
New research investigating the impact of MDD and its treatment on functionality 
and work performance among working adults without comorbidities is needed in 
emerging markets.
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OBJECTIVES: It has been known that depression is associated with significant 
impairments in health-related quality of life (HRQOL). However, few studies have 
evaluated HRQOL dysfunction in both physical and mental health domains. This 
study examined the factors, namely demographic, socio-economic and health-
related factors affecting the physical and mental health domains of HRQOL in 
individuals suffering from depression. METHODS: This retrospective, observa-
tional cross-sectional study used data from the 2011 Medical Expenditure Panel 
